Application of thymalfasin in non-operative treatment of cervical cancer

Abstract

Objective To observe the effect of thymalfasin on non-operative treatment of cervical cancer. Methods Seventy-eight patients with advanced cervical cancer were divided into two groups according to the digital table, each group in 39 cases.The two groups were treated with concurrent chemoradiotherapy. The observation group was given 1.6 mg of thymalfasin subcutaneously each Monday to Friday. While the control group received no additional treatment. And then the two groups were compared in terms of curative effects, adverse reactions, immune states and cellular immune functions. Results The results showed that the differences of curative effects[there were 23 patients in the control group, as compared with 31 patients in the observation group, achieved a complete response(CR), χ2=3.852, P<0.05], adverse reactions(grade Ⅲ or Ⅳ radiation-induced enteritis occurred in 4 patients in the observation group, and 12 patients in the control group, χ2=5.032, P<0.05; Grade Ⅲ or Ⅳ leukopenia occurred in 16 patients in the observation group, and 25 patients in the control group, χ2=4.165, P<0.05; Grade Ⅲ or Ⅳ nausea, vomit occurred in 6 patients in the observation group, and 14 patients in the control group, χ2=4.303, P<0.05), immune states and cellular immune functions between the two groups were significant[the counts of CD3+(t=9.236, P<0.05), CD4+(t=7.445, P<0.05), CD4+ /CD8+ (t=7.445, P<0.05) and NK(t=9.256, P<0.05)] were significantly higher in the observation group after treatment. Conclusion In the treatment of advanced cervical cancer, concurrent chemoradiotherapy combined with thymalfasin can improve the curative effect, reduce the side effects, improve the quality of life and enhance the immunity. Key words: Uterine cervical neoplasms; Antineoplastic combined chemotherapy protocols; Thymalfasin